Reviewed by Dr. Bismah Irfan, MD — June 2026
Your body makes thousands of peptides, and many of them are signaling molecules involved in healing and repair. Peptide therapy has become a popular topic because of that — but it also sits in an unusually messy place: real preclinical science on one side, heavy marketing and unregulated products on the other, and a regulatory picture that is still actively changing. This article tries to give you the honest middle.
In a recent episode of Wellness Focused, I walked through what peptides are, the ones being studied for tissue repair and immune balance, and — most importantly — the safety and regulatory cautions that have to come first.
First, the part most articles bury at the bottom
Before any of the science, you should know where these compounds actually stand. The research peptides discussed most often online — BPC-157, thymosin alpha-1 (TA1), and thymosin beta-4 / TB-500 — are not FDA-approved, and they are not ordinary “wellness” supplements. The FDA placed all three on its interim list of bulk substances flagged for safety concerns, citing potential immune reactions (immunogenicity), manufacturing impurities, and a lack of human safety data (FDA, bulk drug substances for compounding). Their status is in flux — they were removed from that specific list in April 2026 after the nominating companies withdrew, and an FDA advisory committee is scheduled to review them in July 2026 — but the practical takeaway hasn’t changed: these are investigational compounds that should only ever be considered with a qualified physician, not ordered online and self-administered.
With that established, here’s what the science does and doesn’t show.
What Peptides Actually Are
At their simplest, peptides are short chains of amino acids — the building blocks of proteins. But they aren’t complete proteins; they’re much shorter, typically between two and 50 amino acids, and that small size is part of what makes them biologically active.
What sets them apart is that peptides act as biological messengers. They bind to receptors on the surface of your cells and trigger specific responses — influencing things like hormone signaling and immune function. They’re already everywhere in your body: growth hormone is a peptide, insulin is a peptide, and many of the molecules your body uses to regulate itself are peptides. What’s newer in medicine is the ability to synthesize specific peptides and study them as potential therapies.
How They May Differ from Conventional Drugs
The appeal often described is that peptides work with the body’s own signaling rather than overriding a pathway, which may translate to a different side-effect profile. That’s a reasonable hypothesis — but “different” is not the same as “proven safe,” and for most of these peptides the human data simply isn’t there yet to make strong claims either way.
The Peptides Being Studied
BPC-157
BPC-157 (a fragment originally identified in gastric juice) has been studied mainly in animals, where it appears to support new blood-vessel formation, modulate inflammation, and aid tissue repair. The honest summary of the human evidence comes from a 2025 review: “Despite broad preclinical support, human data are extremely limited” — only three small pilot studies exist — and the authors conclude it “should be considered investigational, and its use approached with caution” (PubMed review, 2025). That’s the right frame: biologically interesting, not established.
Thymosin Beta-4 (TB4 / TB-500)
TB4 is naturally present in most cells and is involved in tissue regeneration and cell structure. In preclinical models it has been associated with reduced inflammation and fibrosis. As with BPC-157, the meaningful human safety and efficacy data is not yet available, which is part of why the FDA flagged it.
Thymosin Alpha-1 (TA1)
TA1 is produced by the thymus gland and is studied as an immune modulator — it may help balance immune activity rather than broadly suppress it. It has more clinical history in specific contexts internationally, but in the U.S. it remains in the same investigational, FDA-flagged category for compounded use.
A Useful Point of Comparison
If peptide therapy sounds exotic, it helps to remember that one of the most studied drug classes in the world — the GLP-1 medications used for metabolic health and weight management — are themselves peptides. The key difference is that GLP-1 drugs have been through large human trials and FDA approval, while the research peptides above have not. So the concept of using a precise signaling molecule is well established in mainstream medicine; the specific compounds differ enormously in how much human evidence stands behind them.
A Physician’s Note: How I Approach This
When a patient asks me about peptides, here is roughly how I think about it.
- What I look at first: the foundation — sleep, nutrition, inflammation, and the actual root cause of the problem. Peptides are never step one, and they don’t substitute for that work.
- What I don’t assume: that “natural-sounding” or “investigational” means low-risk. Immunogenicity and product-purity concerns are real, and dosing nuances matter — BPC-157, for instance, can aggravate histamine or mast-cell issues in some people.
- When I would not use them: without baseline testing, without a clear clinical rationale, in pregnancy or breastfeeding, or when the only available source is an unregulated online vendor. Quality and sourcing are not a detail — they’re the whole safety question.
And when someone walks in already injecting a peptide they bought online — which happens more often than you’d expect — my first move isn’t a lecture. It’s to find out exactly what they’re taking, where it came from, and at what dose, because that’s usually where the real risk sits: not in the molecule itself, but in an unverified vial of unknown purity.
An Honest Look at the Limits
Research on most of these peptides is still early and largely preclinical. They are not FDA-approved for the uses people discuss, the regulatory status is unsettled, quality control is a genuine problem, cost is significant (these aren’t covered by insurance), and many require injection. For some people those facts are reason enough to wait. The case for considering them is strongest only in a carefully supervised setting, with realistic expectations.
The Bottom Line
Peptides are a real and interesting area of research, and a few may eventually earn a defined clinical role. Today, the responsible position is measured: treat them as investigational, lead with the foundational work that’s proven to help, and never pursue them outside a knowledgeable clinical relationship.
At iVitality MD in Houston, Dr. Bismah Irfan focuses first on testing, root-cause assessment, and the diet-and-lifestyle foundation — and can talk through where emerging options do and don’t fit a given person’s picture. Book a consultation with iVitality MD →
Selected References
- U.S. Food & Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. fda.gov
- BPC-157: review of preclinical evidence and the limits of human data. 2025. PubMed
- Thymosin beta-4 in tissue repair and regeneration (preclinical review). Annals of the New York Academy of Sciences.
This article is for educational purposes only and is not medical advice, nor a claim to treat or cure any condition. BPC-157, TA1, and TB4/TB-500 are not FDA-approved and have been flagged by the FDA for safety concerns; their regulatory status is changing. Peptides can interact with medications and may be inappropriate with certain health conditions. Always consult a qualified physician before considering any peptide therapy.